Hypocholesterolemia: Blessing or a Problem?
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 3
- By:
- Publication type:
- Article
Works matching IS 17907306 AND DT 2020 AND VI 15 AND IP 1
Results: 16
1
2
SOPHIA primary analysis: A phase 3 study of margetuximab + chemotherapy versus trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 35
- By:
- Publication type:
- Article
3
Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 35
- By:
- Publication type:
- Article
4
KEYNOTE-062: Pembrolizumab With or Without Chemotherapy vs Chemotherapy in Advanced Gastric or GEJ Adenocarcinoma.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 34
- By:
- Publication type:
- Article
5
MONALEESA-7: Addition of Ribociclib to Endocrine Therapy in Premenopausal Women with HR-Positive, HER2-Negative Breast Cancer.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 34
- By:
- Publication type:
- Article
6
Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 33
- By:
- Publication type:
- Article
7
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 33
- By:
- Publication type:
- Article
8
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 32
- By:
- Publication type:
- Article
9
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 32
- By:
- Publication type:
- Article
10
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 32
- By:
- Publication type:
- Article
11
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 32
- By:
- Publication type:
- Article
12
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 31
- By:
- Publication type:
- Article
13
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 31
- By:
- Publication type:
- Article
14
Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 31
- By:
- Publication type:
- Article
15
Efficacy of Infliximab after Failure of Subcutaneous Anti-TNF Agents in Patients with Moderate to Severe Ulcerative Colitis.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 24
- By:
- Publication type:
- Article
16
Red Blood Cell Unit Utilization in the ICU: Evidence and Confidence.
- Published in:
- Hospital Chronicles, 2020, v. 15, n. 1, p. 7
- By:
- Publication type:
- Article